Short answer
Edwards Lifesciences (EW) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Edwards issued third-quarter 2026 financial results on November 4, 2026.
Edwards Lifesciences 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Edwards issued third-quarter 2026 financial results on November 4, 2026
- Investor-relevant figures and management commentary are contained in Exhibit 99.1, the accompanying earnings release
Item EX-99.1 · Exhibit EX-99.1
- Q3 sales $1.72B, up 10.5%, with adjusted EPS $0.80, up 19% year over year
- TAVR sales $1.24B, up 8.0%, supporting continued leadership in Edwards’ core structural-heart franchise
- TMTT sales $207M, up 44.0%, the key growth engine as PASCAL and EVOQUE adoption accelerates
- 2026 guidance raised: sales growth approximately 11.5%, TAVR growth 9.0% to 9.5%, adjusted EPS $2.97 to $3.05
- Q3 included a $220.2M impairment charge, leaving GAAP operating margin 17.4% versus 30.3% adjusted
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edwards Lifesciences 8-K filings
Get the next EW 8-K as it lands
Follow EW for push alerts, or ask the research agent what this filing means.